

CALMARE THERAPEUTICS Inc  
Form 8-K  
March 25, 2019

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): March 25, 2019 (March 25, 2019)

**CALMARE THERAPEUTICS INCORPORATED**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of Incorporation)

**001-08696**  
(Commission File Number)

**36-2664428**  
(IRS Employer  
Identification Number)

**1375 Kings Highway East**  
**Fairfield, CT 06824**  
(Address of principal executive offices)

**203-368-6044**  
(Registrant's Telephone Number)

**N/A**

(Former name or former address, if changed since last report)

Edgar Filing: CALMARE THERAPEUTICS Inc - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01**

**OTHER EVENTS.**

On March 25, 2019, the Registrant issued a press release titled “Calmare Therapeutics Receives Two Favorable Rulings In Delaware Chancery Court.” A copy of the press release is provided in this Form 8-K as Exhibit 99.1.

The information in Item 8.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in Item 8.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

**ITEM 9.01.**

**Financial Statements and Exhibits**

Exhibits.

99.1 Press Release, dated March 25, 2019, titled “Calmare Therapeutics Receives Two Favorable Rulings In Delaware Chancery Court”.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

March 25, 2019

By: /s/ Conrad Mir  
Conrad Mir  
Chief  
Executive  
Officer

